The Firm represented Boston-based MPM BioImpact in connection with the $20 million Series B-2 financing of Deka Biosciences, a Maryland-based biotech company.
Deka announced the successful completion of the round, led by MPM BioImpact, on Sept. 28. Detlev Biniszkiewicz, Ph.D., a managing director of MPM BioImpact, will join Deka’s board. Other participating investors included Leaps by Bayer, Lumira Ventures and O-Bio (Echo Investment Capital).
Founded in 2018, Deka Biosciences is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases.
Deka will use the proceeds to support the advancement of its pipeline and drug product manufacturing. With this financing, Deka will continue clinical trials for its new investigational new drug application to treat tumors, for which it has received a notice to proceed from the U.S. Food and Drug Administration (FDA).
Boston-based MPM BioImpact is a biotechnology investment firm founded in 1996 that invests in innovate biotechnology companies that are seeking to deliver transformative therapies to patients in the areas of highest unmet medical need.
Brown Rudnick attorneys Michael Cohen and Tyler Horowitz worked on the deal.
